On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Sorrento Therapeutics, Inc. (NASDAQ: SRNE) Enriching Lives through Scientific Innovation

Company: Sorrento Therapeutics, Inc. (SRNE)
Category: Stock Spotlights

California-based biopharmaceutical company Sorrento Therapeutics (NASDAQ: SRNE) has a portfolio of OnTarget immunotherapies comprised of intracellular antibodies, immune checkpoint inhibitors, bispecific antibodies, and antibody-drug conjugates, as well as chimeric antigen receptor (CAR)-based cellular therapies. Through its TNK Therapeutics subsidiary, the company is also advancing adoptive cellular therapies utilizing the T cell as well as the Natural Killer cell. Sorrento has partnered with the City of Hope to form a joint venture, LA Cell, which is developing cell-internalizing mAbs against undruggable intracellular targets. Sorrento’s lead programs are four late-stage biosimilar and biobetter antibodies targeting an established market of more than $13 billion, and two early-stage CAR-T therapies targeting solid tumors. Along with these products, Sorrento has a portfolio of preclinical immuno-oncology antibody programs and antibody drug conjugates. It is also developing resiniferatoxin, a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease.

To learn more, visit www.sorrentotherapeutics.com

About Sorrento Therapeutics, Inc.

Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases. Sorrento’s lead product candidates are clinical oncolytic virus and CAR-T therapies targeting solid tumors, late-stage pain medicine, as well as late-stage biosimilar and biobetter antibodies.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, visit https://www.networknewswire.com.

Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217